Nanocarriers for vascular delivery of anti-inflammatory agents.
Nanocarriers for vascular delivery of anti-inflammatory agents.
复制标题
用于血管输送抗炎剂的纳米载体。
DOI：
10.1146/annurev-pharmtox-011613-140002
复制
发表时间：
2014
影响因子：
12.5
通讯作者：
Muzykantov VR
中科院分区：
文献类型：
--
作者：
Howard MD;Hood ED;Zern B;Shuvaev VV;Grosser T;Muzykantov VR
有必要改进对急性血管炎症的治疗，如缺血再灌注损伤、急性肺损伤、脓毒症和中风。血管内皮细胞在这些情况下是一个重要的治疗靶点。此外，一些抗炎药(AIAs)(例如生物疗法)需要精确地输送到亚细胞隔室。从理论上讲，对所需行动地点的优化交付可能会改善这些AIA的效果，并使新的行动机制成为可能。为此，人们设计并探索了多种纳米载体(NCs)及其对内皮细胞的靶向策略。在动物模型中的研究表明，使用NCS传递AIAS可能在炎症途径中提供有效和特异的分子干预。然而，复杂的NC-AIA制剂的工业开发和临床翻译是具有挑战性的。有必要对治疗/副作用和收益/成本比进行严格的分析，以确定和优化可能在急性炎症管理中找到临床实用的方法。
There is a need for improved treatment of acute vascular inflammation in conditions such as ischemia-reperfusion injury, acute lung injury, sepsis, and stroke. The vascular endothelium represents an important therapeutic target in these conditions. Furthermore, some anti-inflammatory agents (AIAs) (e.g., biotherapeutics) require precise delivery into subcellular compartments. In theory, optimized delivery to the desired site of action may improve the effects and enable new mechanisms of action of these AIAs. Diverse nanocarriers (NCs) and strategies for targeting them to endothelial cells have been designed and explored for this purpose. Studies in animal models suggest that delivery of AIAs using NCs may provide potent and specific molecular interventions in inflammatory pathways. However, the industrial development and clinical translation of complex NC-AIA formulations are challenging. Rigorous analysis of therapeutic/side effect and benefit/cost ratios is necessary to identify and optimize the approaches that may find clinical utility in the management of acute inflammation.